Chiesi Farmaceutici

Privately held: no public share price

Assets

(7 total)
7Total Assets
4Approved
1Phase 3 / Filed
2Phase 1–2 / Early
7Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Approved
Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Small molecule
Chronic Obstructive Pulmonary DiseaseAsthma
Cangrelor(Kengreal)
Approved
P2Y12 receptorSmall molecule
Atherosclerotic Cardiovascular Disease
Lomitapide(Juxtapid)
Approved
MTPSmall molecule
Homozygous Familial Hypercholesterolemia
Approved
Alpha-galactosidase A (GLA / α-Gal A)Protein / enzyme therapeutic
Fabry Disease
Phase 3
Glucocorticoid receptor; β2-adrenergic receptorSmall molecule
Chronic Obstructive Pulmonary DiseaseAsthma
metreleptin(Myalept)
Phase 2
LeptinProtein / enzyme therapeutic
Obesity
Phase 1/2
dopamine precursor · aromatic L-amino acid decarboxylase (AAAD; DOPA decarboxylase)Small molecule
Parkinson's Disease

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
pegunigalsidase alfaPhase 2/3Fabry Disease
Est. primary completion 2027-10 · NCT05710692 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
metreleptin · MyaleptPhase 3Familial Partial Lipodystrophy
Est. primary completion 2028-03 · NCT06679270 · CT.gov ↗
What to watch
October 2028 (2)
pegunigalsidase alfaPhase 2/3Fabry Disease
Est. primary completion 2028-10 · NCT06328608 · CT.gov ↗
What to watch
Est. primary completion 2028-10-17 · NCT07546981 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

February 2026ApprovalLomitapideFDA updates Boxed Warning on Juxtapid (NDA203858)
US, FDA · FDA · Source ↗

Financial reports

No financial reports recorded.